A stormy run in two days! Today, the stock rose 17%. Why are you buying shares of this company worth ₹19,000 crore? The impact of the news on the exchange.

News Topical, Digital Desk : A stock has become a major topic of discussion in the market. On April 27th, the stock was locked in an upper circuit of 20%, and its upward movement continued on April 28th. The stock opened at ₹444.45 in the morning, compared to its previous close of ₹432.10. Subsequently, there was heavy buying, pushing the stock past ₹510. The upper circuit is set at ₹518.50. At the time of writing this news, at 9:57 am, the stock was trading up nearly 17%.

Share Movement
27 Apr Close Price ₹360.10
27 Apr High ₹432.10
April 28 Open ₹444.45
April 28 Intraday ₹510+ Upper Circuit Level ₹518.50 All-Time High ₹1360 

Why did the stock surge? 

The biggest reason for this surge is a major management announcement made by the company. Cohance Lifesciences has announced the appointment of former Umang Vohra as Executive Chairman. He will assume this new role effective May 1, 2026. He will also assume the position of Group CEO effective May 20, 2026. Umang Vohra is a prominent figure in the pharmaceutical industry. He previously served as the Chief Executive Officer of Cipla. The market viewed this appointment as a positive sign for the company's future, leading to a wave of buying in the stock. 

How did the stock perform on April 27? 

Previous closing price: Rs. 360.10 Open: Rs. 380.35 Day's high: Rs. 432.10
Upper Circuit: +20%
Normal Volume: 4.8 million shares
Volume till 10:00 AM: 20 million shares
This clearly indicates that not only the price but also the volume has seen a significant surge. High volume often indicates that the market is taking news seriously.

What does the company do?
Cohance Lifesciences is a technology-based integrated CDMO platform. The company operates in areas such as complex chemistry, API development, ADCs, oligonucleotides, and life science solutions. This means it is in the pharmaceutical and research-based high-value business.

What do past records indicate?
The stock's all-time high is ₹1,360, while its all-time low is ₹87.60. A 15% gain in the last three months, a 60% decline in one year , and an 8% decline in three years
mean that the recent rally is strong, but the stock appears to be in recovery mode in the long term.

What do promoter and FII holdings indicate?
The promoters' stake in the company stood at 57.49% as of March 2026. This has remained stable over the past three quarters. However, it declined from 66.41% in May 2025, a decrease over the past year. The share of foreign investors (FIIs) also declined from 7.38% to 5.59%, indicating that foreign investors had adopted a cautious stance in the recent past.

What does it signal for investors?
The market often views the entry of experienced leadership as positive. Investors hope that new management can provide new impetus to the company's strategy, revenue, and expansion plans. However, a rally based on news alone does not last long. The company's results, profits, order book, and growth plans will be more important going forward. Currently, the two-day rally in Cohance Lifesciences has made it a market star stock.

Read More: HUL Q4 Results 2026: HUL quarterly results released, dividend of Rs 22, stock crash